Novartis Plans to Build Swiss Facility After Kymriah Approval

Following the European Commission’s approval of Novartis’ Kymriah for two distinct indications in the EU, the drugmaker announced plans to build a new biotechnology center in Stein, Switzerland.

The new center will cost approximately $92 million and will employ up to 450 workers in three years. The company expects to deliver its first products from the new facility in early 2020.

The first CAR-T cell therapy approved by the FDA, Kymriah uses the patient's own T cells to fight cancer.